ArticleCancer immunology, immunotherapy : CII2008
CRMP5 antibodies in patients with small-cell lung cancer or thymoma.
Article in Cancer immunology, immunotherapy : CII, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 34 citations in OpenAlex.
- Paraneoplastic neuromyelitis optica spectrum disorder with dual AQP4-IgG and CRMP5 antibodies following thymectomy: a case report.Frontiers in neuroscience · 2026Article
- Initial screening for neuronal autoantibodies and their putative impact on survival in patients with small-cell lung cancer.Thoracic cancer · 2024Article
- An overview on CV2/CRMP5 antibody-associated paraneoplastic neurological syndromes.Neural regeneration research · 2023Article
- Concurrent Ocular Myopathy and Myasthenia Gravis After Zimberelimab Therapy in a Patient With Non-Small-Cell Lung Cancer.Journal of clinical neurology (Seoul, Korea) · 2022Article
- CRMP5 regulates cell proliferation and development of colorectal cancer via MAPK-dependent signaling.Oncology letters · 2021Article
- Anti-CRMP5 paraneoplastic chorea: selective external capsule MRI involvement resolving after tumour resection.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Article
- CRMP5 Antibodies-Diagnostic Challenges.Frontiers in neurology · 2021Article
- Autoantibodies as diagnostic biomarkers for lung cancer: A systematic review.Cell death discovery · 2019Review
- Paraneoplastic neurological syndromes associated with ovarian tumors.Journal of cancer research and clinical oncology · 2015Review
- Collapsin response mediator proteins: Potential diagnostic and prognostic biomarkers in cancers (Review).Oncology letters · 2014Article
- Detection of autoantibodies against heat shock proteins and collapsin response mediator proteins in autoimmune retinopathy.BMC ophthalmology · 2013Article
- Avidity of onconeural antibodies is of clinical relevance.Cancer immunology, immunotherapy : CII · 2013Article
- Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy.Molecular cancer · 2011Review
- Antibody to CCDC104 is associated with a paraneoplastic antibody to CDR2 (anti-Yo).Cancer immunology, immunotherapy : CII · 2010Article
- Onconeural antibodies in sera from patients with various types of tumours.Cancer immunology, immunotherapy : CII · 2009Article
- Paraneoplastic Limbic Encephalitis Associated with Anti-CV2/CRMP5 Antibodies Secondary to Thymoma in an Adolescent.Case reports in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The collapsin response mediator protein 5 (CRMP5) antibody is usually associated with paraneoplastic neurological syndrome (PNS) and small-cell lung cancer (SCLC) or thymoma. The objective of this study was to assess the frequency of CRMP5 antibodies in patients with such tumours and to see if the presence of antibodies was associated with prognosis in these cancers. A multi-well adapted immunoprecipitation assay using radiolabelled recombinant CRMP5 protein, produced by coupled in vitro transcription/translation, was used for the detection of CRMP5 antibodies. Sera from 200 patients with SCLC, 73 patients with thymoma and myasthenia gravis (MG) and from 300 healthy blood donors were examined for CRMP5 antibodies. Positive sera were also examined by immunofluorescence and immune blots. The serological results were compared with disease severity of the patients with thymoma or SCLC. CRMP5 antibodies were detected in 10/200 (5%) of the SCLC, 9/73 (12%) of the thymomas and in 2/300 (0.6%) of the healthy controls by immunoprecipitation. The antibodies were less frequently detected by immunofluorescence or immune blots. There was no significant correlation between CRMP5 antibodies and disease severity. CRMP5 antibodies are more than twice as frequent, and the antibody levels are higher in patients with thymoma and MG than in patients with SCLC. The antibodies are correlated to these tumours, but not to disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.